Vaginal Estrogen for Female Sexual Function & Libido — Libido & Sex
FDA-approved local estrogen therapy for treating vulvovaginal atrophy, painful intercourse, and restoring sexual function in postmenopausal women.
Overview
Low-dose vaginal estrogen is a localized hormone therapy that delivers estradiol (E2), conjugated estrogens, or estriol directly to vaginal tissues. It's FDA-approved for treating genitourinary syndrome of menopause (GSM), also called vulvovaginal atrophy - a condition affecting 40-57% of postmenopausal women. Low-dose local formulations (creams, tablets, Estring ring) work locally with minimal systemic absorption (<10%), making them safer than oral/transdermal HRT. These products restore vaginal tissue health, elasticity, lubrication, pH balance, and blood flow - directly addressing dyspareunia (painful sex), dryness, and diminished sexual desire. Clinical studies show 80-90% improvement in sexual function scores, vaginal health indices, and quality of life.
Indications
- Vulvovaginal atrophy (genitourinary syndrome of menopause)
- Painful intercourse (dyspareunia) due to vaginal dryness
- Low libido related to vaginal discomfort or atrophy
- Vaginal dryness, burning, itching
- Urinary symptoms (urgency, frequency, recurrent UTIs)
- Restoration of sexual function and satisfaction
Mechanism of Action
Estrogen deficiency causes vaginal tissue thinning, dryness, pH elevation, and painful intercourse
Dosing
| Compound | Dose | Frequency | Notes |
|---|---|---|---|
| Estrace Cream (0.01% estradiol) | 1-2 grams (0.1-0.2 mg estradiol) | Nightly for 2 weeks, then 1-3x weekly | Most common formulation; titrate to lowest effective dose |
| Premarin Cream (0.625 mg/g) | 0.5-1 gram | Nightly for 2 weeks, then 2-3x weekly | Alternative to estradiol; similar efficacy |
| Vagifem (10 mcg estradiol) | 10 mcg tablet | Nightly for 2 weeks, then 2x weekly | Ultra-low dose; minimal mess; preferred by many patients |
| Estring (7.5 mcg/day estradiol) | One ring | Replace every 90 days | FDA-approved; minimal systemic absorption; most convenient local option |
| Femring (0.05-0.1 mg/day estradiol) | One ring | Replace every 90 days | FDA-approved but DELIVERS SYSTEMIC ESTROGEN - FDA boxed warnings apply (VTE, stroke, cancer risk); for combined vaginal/systemic symptoms only |
| Estriol 0.5-1 mg/g gel | 0.5-1 gram | Nightly for 2-4 weeks, then 2-3x weekly | NOT FDA-approved in US; popular in Europe; available via compounding pharmacy; weaker estrogen |
Evidence Grade
GRADE A
Safety & Contraindications
- Low-dose local formulations (Vagifem, Estring, low-dose creams) have excellent safety profile
- Minimal systemic absorption (<10% for low-dose products) - safer than oral/transdermal HRT
- Breast cancer survivors: Requires individualized oncology consultation; some products may be approved on case-by-case basis per NCCN/ASCO guidelines
- Contraindicated: Undiagnosed vaginal bleeding, active estrogen-dependent malignancy
- Common side effects: Mild vaginal discharge, irritation (usually transient)
- Low-dose local products: No increased cardiovascular or thromboembolic risk in most studies
- IMPORTANT: Higher-dose rings (Femring) deliver systemic estradiol and carry FDA boxed warnings for VTE, stroke, CV events, and breast cancer risk
- Can be used long-term with low-dose local formulations; regular monitoring recommended
- Breast tenderness rare but possible, more common with higher systemic absorption products